A clinical stage pharmaceutical company, KalVista Pharmaceuticals appoints Nancy Stuart as its Board of Directors. She has taken charge to its Board of Directors with effect from March 18, 2021.This move has been initiated in order to focus on the discovery, development and commercialization of small molecules protease inhibitors.

Before joining KalVista, Nancy served as Chief Operating Officer at Concert Pharmaceuticals and has been a leader in strategic planning, business operations and business development in the biopharmaceutical and biotechnology industries.

Andrew Crockett, Chief Executive Officer KalVista says, “We are pleased to welcome Nancy to our Board of Directors. Her experience at a broad range of companies from both a strategic and operational perspective will be valuable. Our portfolio of clinical-stage assets has grown, and we look forward to Nancy’s input to help us as we evolve into a commercial-stage organization with our oral HAE franchise.”

Nancy brings in more than 25 years of experience in the biotechnology and pharmaceutical industry that include tactical, operational and development activities. Before joining Concert, she held senior business and drug development positions in large and small biotechnology and clinical development companies namely Amgen Inc., Genzyme Corp and Vertex Pharmaceuticals. Furthermore, she also serves on the Board of Directors of The Greater Boston YMCA. Nancy obtained M.B.A. from the Simmons College Graduate School of Management and her B.S. from the University of Michigan.

Commenting on her new role, Nancy states, “I am delighted to join the KalVista Board at such a transformational point. The recent positive data shown with KVD900 as an oral on-demand treatment for HAE attacks marks such an important advancement for patients. I am proud to be a part of the process to bring KVD900 and other efficacious oral treatments forward.”